Matthew McClure
Net worth: 74 605 $ as of 2024-04-29
Profile
Matthew W.
McClure worked as a Senior Director at Alios BioPharma, Inc. from 2012 to 2018.
He then served as the Chief Medical Officer at Second Genome, Inc. from 2018 to 2019.
Currently, he is the Chief Medical Officer & Executive Vice President at Aligos Therapeutics, Inc. starting from 2019.
Dr. McClure completed his undergraduate studies at the University of California San Diego and obtained his doctorate degree from Duke University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-29 | 91,204 ( 0.13% ) | 74 605 $ | 2024-04-29 |
Former positions of Matthew McClure
| Companies | Position | End |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-05-08 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | General Counsel | 2019-05-31 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Director/Board Member | 2018-02-28 |
Training of Matthew McClure
| University of California San Diego | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Matthew McClure
